Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oasis Flow: TAK-085 in Hyperlipidemia
NCT02824432Phase 4Completed
- Sponsor
- Takeda
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of doconexent ethyl in hyperlipidemia, hypertriglyceridemia, sponsored by Takeda. Started Aug 2016; status: completed.
02
Drugs
doconexent ethyl
03
Conditions
hyperlipidemiahypertriglyceridemia
Beyond the preview
Go deeper on NCT02824432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824432.